The Global Network for Public Interest Law is seeking nominations for the second annual European Award for Partnership in the Public Interest, which will recognize the best pro bono legal project (or projects) undertaken jointly between a non-governmental organization and a law firm in Europe.
The conference was a very important and useful meeting that was attended by professionals, care providers and policy makers from across South East Europe.
The campaign “Drug Law: it’s time to change” will collect 1 million signatures to present Brazil’s National Congress with a bill calling for more equitable and effective drug legislation in the country.
A campanha “Lei de Drogas: É Preciso Mudar” vai recolher 1,3 milhão de assinaturas para apoiar o Projeto de Lei que será apresentado ao Congresso Nacional com o objetivo de tornar a legislação sobre drogas no país mais justa e eficaz.
The harm reduction programme developed by Medecins du Monde in Afghanistan since 2006 was handed over to the Organisation for Harm Reduction in Afghanistan.
The Editorial Team of the The International Journal of Prisoner Health calls for papers to increase the quantity and quality of submissions to the journal.
This is a short summary of the 2nd Annual Conference of COPOLAD, an ambitious project which seeks to increase dialogue and cooperative work between governments from Latin America and the European Union.
Since 2011, CIDDH has implemented a hotline called The Green Line (or Línea Verde in Spanish) which provides legal information and assistance to all Peruvians who are questioned and arbitrarily arrested for drug use (mostly cannabis).
Taking place only a few weeks after the NATO Summit in Chicago in May 2012, an event where discussion of counter-narcotics policy was noticeably absent, the IDPC-funded International Institute of Strategic Studies colloquium succeeded in stimulating discussion on an issue area that has currently dropped off the policy radar.
The new legislation will reduce risks to the public by removing untested and potentially harmful products from being sold and introducing a pre-market approval scheme with testing requirements and retail restrictions for low-risk psychoactive substances.
